ESSA Pharma Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EPIX research report →
Companywww.essapharma.com
ESSA Pharma Inc. , a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer.
- CEO
- David Ross Parkinson
- IPO
- 2015
- Employees
- 35
- HQ
- Vancouver, BC, CA
Price Chart
Valuation
- Market Cap
- $9.52M
- P/E
- -0.47
- P/S
- 0.00
- P/B
- 0.08
- EV/EBITDA
- 3.85
- Div Yield
- 839.96%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -16.63%
- ROIC
- -20.26%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-28,542,821 · -7.38%
- EPS
- $-0.64 · -6.67%
- Op Income
- $-34,421,017
- FCF YoY
- -14.83%
Performance & Tape
- 52W High
- $6.45
- 52W Low
- $0.18
- 50D MA
- $0.83
- 200D MA
- $1.49
- Beta
- 1.53
- Avg Volume
- 6.75M
Get TickerSpark's AI analysis on EPIX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 9, 25 | Parkinson David Ross | sell | 65,675 |
| Oct 9, 25 | Wood David S. | sell | 33,343 |
| Oct 9, 25 | BERGER FRANKLIN M | sell | 784,404 |
| Oct 9, 25 | Glickman Richard M | sell | 43,240 |
| Oct 9, 25 | Requadt Scott | sell | 30,002 |
| Oct 9, 25 | Martin John Alexander | sell | 14,299 |
| Oct 9, 25 | Thorell Marella | sell | 2,881 |
| Oct 9, 25 | BVF PARTNERS L P/IL | other | 560,797 |
| Aug 5, 25 | BVF PARTNERS L P/IL | other | 1,481,634 |
| Aug 5, 25 | BVF PARTNERS L P/IL | sell | 79 |
Our EPIX Coverage
We haven't published any research on EPIX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate EPIX Report →